A Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimodal Data

April 25, 2026 updated by: Shanghai Zhongshan Hospital

The goal of this observational study is to learn if combining information from CT scans, blood tests, and pathology reports can better predict how pancreatic cancer will progress.

The main questions it aims to answer are:

  • Can combining these types of data more accurately estimate how long a person might survive?
  • Can it better predict the risk of the cancer coming back?

Participants will not have any extra tests or treatments. They will:

  • Allow researchers to collect information from their existing medical records (such as surgery reports, imaging, and lab results)
  • Receive a follow-up phone call about every 3 months for up to 3 years to share health updates

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

1030

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, China
        • Recruiting
        • Zhongshan Hospital Affiliated to Fudan University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

The study population will be drawn from patients receiving surgical treatment for pancreatic cancer at two academic medical centers in China: the Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University (Shanghai) and the Third Xiangya Hospital, Central South University (Changsha). The retrospective cohort includes patients diagnosed between January 2023 and December 2025, identified from hospital electronic health records. The prospective cohort will comprise newly diagnosed patients enrolled consecutively. Both cohorts originate from the same clinical settings, representing a tertiary hospital-based population with consistent diagnostic and treatment standards.

Description

Inclusion Criteria:

  • Age ≥ 18 years.
  • Histologically or cytologically confirmed diagnosis of pancreatic cancer.
  • Availability of preoperative and postoperative contrast-enhanced CT images at the participating center; patient records include corresponding clinical data, postoperative pathological reports, and preoperative and postoperative blood test results.
  • Underwent surgical treatment for pancreatic cancer at a participating center of this study.

Exclusion Criteria:

  • Age < 18 years (minors).
  • Presence of other severe diseases (e.g., severe liver or kidney failure, cardiovascular or cerebrovascular diseases, malignancies other than pancreatic cancer); pregnant or breastfeeding women; individuals with mental illness;
  • patients unable to comply with follow-up or provide informed consent.
  • Presence of significant outliers (e.g., laboratory values exceeding 10 times the normal range without clinically reasonable explanation) or samples with excessive missing data.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Retrospective cohort
prospective cohort

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
overall survival
Time Frame: 3 years
3 years
recurrence free survival
Time Frame: 3 years
3 years
recurrence status within one year after surgery
Time Frame: 3 years
3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Shanghai Zhongshan Hospital

Collaborators

First Affiliated Hospital Xi'an Jiaotong University
The First Affiliated Hospital of University of South China

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 8, 2025

Primary Completion (Estimated)

July 31, 2029

Study Completion (Estimated)

December 31, 2029

Study Registration Dates

First Submitted

April 25, 2026

First Submitted That Met QC Criteria

April 25, 2026

First Posted (Actual)

May 1, 2026

Study Record Updates

Last Update Posted (Actual)

May 1, 2026

Last Update Submitted That Met QC Criteria

April 25, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • B2026-107(2)R

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pancreatic Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe